Pharma deal potentially great news, but there are worries over funding
1 December 2025
Daniel Elkeles responds to the UK-US pharmaceuticals deal.
Finance
Prevention
Responding to the announcement of the UK-US pharmaceuticals deal, the chief executive of NHS Providers, Daniel Elkeles, said:
"This deal is potentially very good news for patients, for the NHS and for UK life sciences.
"It is great that NHS patients will have increased access to groundbreaking new treatments.
"The announcement also builds on the longstanding close partnership between the NHS and the pharmaceutical industry, making this the best place in the world to carry out clinical trials.
"However it is not yet clear how it will be paid for.
"There is absolutely no slack in current published NHS spending plans for this major commitment and that is a real worry for trust leaders."
Related articles
- News
Underfunding mental health is not just bad for patients but for wider communities and economy, health leaders say
12 Mar 2026Rebecca Gray, mental health director speaking on behalf of the NHS Confederation and NHS Providers responded to the government’s announcement on mental health spending.
Mental health
Finance
Delivery and performance
Health inequalities
- News
Funding pressures putting NHS progress at risk
3 Mar 2026Dr Layla McCay responds to the chancellor's spring statement.
Finance
InsightsPublic Accounts Committee inquiry on the New Hospital Programme: submission from NHS Providers
12 Feb 2026This submission to the Public Accounts Committee outlines our view on the New Hospital Programme and the impact of continued delays.
Finance